

IN THE UNITED TRANSPER PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Application No.: 09/070,629 Group Art Unit: 1642

Filed: April 30, 1998 Examiner: Ungar, S.

For: RECOMBINANT INFLUENZA Atty. Docket No.: 6923-071

VIRUSES EXPRESSING TUMOR-ASSOCIATED ANTIGENS AS

ANTITUMOR AGENTS

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Box Sequence

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures (hereinafter the "Notice to Comply") mailed by the United States Patent and Trademark Office on June 22, 1999, in connection with the above-identified application, Applicants submit herewith: (1) a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. §1.821(c), (d) and (e), respectively; and (2) a return copy of the Notice to Comply (Form PTO-1661).

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c), (d) and (e), respectively, are the same. I hereby state that the submission herein under 37 C.F.R. §1.821(g) does not include new matter.

It is estimated that no fee is required for filing this Response. In the event a fee is due, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150.

Respectfully submitted,

by: Deequeline Ben Reg No. 43, was d. Coreszi 30

Laura A. Coruzzi

(Reg. No.)

PENNIE & EDMONDS LLP

1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Enclosures

Date: October 22, 1999

- 2 -

NY2 - 1008888.1

OCT 2 2 1999

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND REQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

الكا	-1. This application clearly fails to comply with the requirements of 37 CFR 1.821
- 1.8 May 1	25. Applicant's attention is directed to these regulations, published at 1114 OG 29 5, 1990 and at 55 FR 18230, May 1, 1990.
\Box	
لــا	2. This application does not contain, as a separate part of the disclosure on
paper	copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been
submi	tted as required by 37 CFR 1.821(e).
******	4. A copy of the "Sequence Listing" in computer readable form has been submitted.
of 37	er, the content of the computer readable form does not comply with the requirements CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw nce Listing."
اللا	5. The computer readable form that has been filed with this application has been
Repor 1.825	to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem t. A substitute computer readable form must be submitted as required by 37 CFR (d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer
readal	ole form of the "Sequence Listing" as required by 37 CFR 1.821(e).
□.	7.
Other	
3 1	
Applicant must provide:	
<u> </u>	An initial or substitute computer readable form (CRF) copy of the "Sequence
Listin	ng"
	An initial or substitute paper copy of the "Sequence Listing", as well as an
$\overline{}$	amendment directing its entry into the specification
	A statement that the content of the paper and computer readable copies are the same
	and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)
For q	uestions regarding compliance with these requirements, please contact:

Please return a copy of this notice with your response.

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212 For PatentIn software help, call (703) 557-0400